



INSIDE THIS ISSUE

- [Benefit Drug List](#)
- [Revised Process for Undesignated Indication Approval](#)
- [Protocol Update](#) – UBRAVTR, BRAVTRNAV, CNIME, ENAVD, GIIRFUFA, GUSCARB, LUDOC
- [Cancer Management Manual](#) – Primary Unknown Tumour
- [Pre-Printed Order Update](#) – GIA, GIEFUP, GIENDO2, GIIR, GIIRFUFA, GOOVTOP, GUSCARB, LYCYCLO
- [Patient Education](#) – Breast Cancer
- [Drug Update](#) – Cytarabine, Pamidronate, Trastuzumab
- [Cancer Drug Manual](#)
- [Supportive Care](#) – Filgrastim Assistance Program
- [Provincial Systemic Therapy Program Policies](#)
- [Library/Cancer Information Centre](#)

FAX request form and IN TOUCH phone list are provided if additional information is needed.

BENEFIT DRUG LIST

The current Benefit Drug List and Class II forms are available on the website www.bccancer.bc.ca.

REVISED PROCESS FOR UNDESIGNATED INDICATION APPROVAL

Please note that all undesignated drug applications should now be faxed to Dr. Suzanne Taylor at (604) 877-6132, who will triage all requests in collaboration with the BC Cancer Agency Tumour Group designate and the Systemic Therapy Program Leader or designates. For more details, please refer to the letter attached. A revised “Undesignated Indication” approval form can be obtained via H-drive at regional cancer centres, our website, or Fax-back as listed at the end of the Update.

PROTOCOL UPDATE

Protocols by Drugs Index A cross-referenced index lists the BC Cancer Agency benefit drugs with their corresponding protocols. This index can be obtained via H-drive at regional cancer centres or Fax-back as listed at the end of the Update.

Protocol codes for treatments requiring “Undesignated Indication” approval prior to use are prefixed with the letter **U**.

- **INDEX to BC Cancer Agency Protocol Summaries** revised monthly (includes tumour group, protocol code, indication, drugs, last revision date and version)
- **UBRAVTR** revised (process for adding BCCA benefit drugs clarified): Palliative therapy for metastatic breast cancer using trastuzumab (Herceptin®)
- **BRAVTRNAV** revised (duration of treatment and process for continuing single agent trastuzumab clarified): Palliative therapy for metastatic breast cancer using trastuzumab (Herceptin®) and vinorelbine
- **CNIME** revised (typos corrected in Dose Modifications): Ifosfamide, mesna and etoposide in the treatment of recurrent brain tumours
- **ENAVD** new (formalised): Palliative therapy for advanced endocrine cancers using doxorubicin
- **GIIRFUFA** revised (dose modifications): First-line palliative combination chemotherapy for metastatic colorectal cancer using irinotecan, fluorouracil and folinic acid (leucovorin)
- **GUSCARB** revised (eligibility): Adjuvant therapy for stage I high risk seminoma using carboplatin
- **LUDOC** revised (eligibility): Second-line treatment for advanced non-small cell lung cancer (NSCLC) with docetaxel (Taxotere®)

Protocols are available on the BC Cancer Agency website www.bccancer.bc.ca/ccp/.

CANCER MANAGEMENT MANUAL

Primary Unknown Tumour Entire section has been updated.

The Cancer Management Manual is available on BC Cancer Agency website www.bccancer.bc.ca/cmm/.

PRE-PRINTED ORDER UPDATE

Pre-printed orders should always be checked with the most current BC Cancer Agency protocol summaries. The Vancouver Cancer Centre has prepared the following chemotherapy pre-printed orders, which can be used as a guide for reference:

- **GIA** revised (premed dexamethasone dose): Palliative therapy for hepatoma using doxorubicin
- **GIEFUP** revised (premed dexamethasone dose): Combined modality therapy for locally advanced esophageal cancer using fluorouracil and cisplatin
- **GIENDO2** revised (premed dexamethasone dose): Palliative therapy for pancreatic endocrine tumours using streptozocin and doxorubicin
- **GIIR** revised (premed dexamethasone dose): Second-line palliative treatment for fluorouracil-refractory metastatic colorectal cancer using irinotecan
- **GIIRFUFA** revised: First-line palliative combination chemotherapy for metastatic colorectal cancer using irinotecan, fluorouracil and folinic acid (leucovorin)
- **GOOVTOP** revised: Treatment of relapsed/progressive epithelial ovarian, fallopian tube or primary peritoneal cancer using topotecan
- **GUSCARB** new: Adjuvant therapy for stage I high risk seminoma using carboplatin
- **LYCYCLO** new: Therapy of lymphoma, Hodgkin's disease, chronic lymphocytic leukemia or multiple myeloma using cyclophosphamide

An index to the orders can be obtained by Fax-back.

PATIENT EDUCATION

Breast Cancer The patient information section for breast cancer on the BC Cancer Agency website has been revised and is available on BC Cancer Agency website www.bccancer.bc.ca/cid.

DRUG UPDATE

Cytarabine Preparation and stability for cytarabine syringes have been standardised in the regional cancer centres of the BC Cancer Agency. Cytarabine 100 mg powder vial is to be reconstituted with 1 mL bacteriostatic water for injection. The reconstituted solution and syringe are stable for 15 days at room temperature.

Pamidronate Effective 10 September, the BCHS contract for pamidronate has been awarded to Faulding. Please ensure that your pharmacy purchaser is aware of this when current supplies have run out.

Trastuzumab Please note that the UBRAVTR protocol requires that trastuzumab be stopped in patients whose systemic disease progresses. The paclitaxel-trastuzumab regimen (BRAVTRAP) should be used prior to UBRAVTR. The vinorelbine-trastuzumab regimen (BRAVTRNAV) is reserved for patients who are ineligible for BRAVTRAP.

CANCER DRUG MANUAL

The Cancer Drug Manual is available on the BC Cancer Agency website www.bccancer.bc.ca/cdm/.

SUPPORTIVE CARE

Filgrastim Assistance Program The Neupogen® Care Program for British Columbia has a toll-free, 24-hours, 7 days a week, phone line (1-888-706-4717) answered by reimbursement specialists who can help investigate if the patient is covered by private or provincial drug plan and whether financing is needed for co-payments and deductibles. For more information, call toll-free 1-800-665-4273 local 511 or see program enrollment form (attached).

PROVINCIAL SYSTEMIC THERAPY PROGRAM POLICIES

BC Cancer Agency Systemic Therapy Policies are available at <h:\everyone\systemic\prov\chemo\policies> on the H-drive at the regional cancer centres and on www.bccancer.bc.ca/ccp/appendices.shtml in the BC Cancer Agency website.

LIBRARY/CANCER INFORMATION CENTRE

Unconventional Cancer Therapies Manual is available on the BC Cancer Agency website www.bccancer.bc.ca/uct/. The manual consists of 46 short monographs on the more commonly used unconventional cancer therapies (e.g., Essiac, vitamins, teas, shark cartilage) and includes tips for the patient and family on how unconventional therapies can be evaluated. For each therapy the

manual provides proponent/advocate claims, as well as evidence-based evaluation/critique quotations from the literature.

Editorial Review Board

Mário de Lemos, PharmD (Editor)

Sharon Allan, MD

Sandi Broughton, BA(Econ), MSc

Jack Chritchley, MD

Karen Janes, MSN

David Noble, BSc, BLS

Jaya Venkatesh, BCom, BA, MHA

Susan Walisser, BSc(Pharm)

Gigi Concon (Secretary)

IN TOUCH	www.bccancer.bc.ca	bulletin@bccancer.bc.ca
BC Cancer Agency	(604)-877-6000	Toll-Free 1-(800)-663-3333
Communities Oncology Network	Ext 2744	jchritch@bccancer.bc.ca
Nursing Professional Practice	Ext 2623	ilundie@bccancer.bc.ca
Pharmacy Professional Practice	Ext 2247	gconcon@bccancer.bc.ca
Provincial Systemic Therapy Program	Ext 2247	gconcon@bccancer.bc.ca
Communities Oncology Network Pharmacist	Ext 2515	francish@bccancer.bc.ca
Drug Information	Ext 3028	robrien@bccancer.bc.ca
Library / Cancer Information	Ext 2690	dnoble@bccancer.bc.ca
Update Editor	Ext 2288	mdelemos@bccancer.bc.ca
Cancer Centre for the Southern Interior (CCSI)	(250) 712-3900	Toll-Free 1-(888)-563-7773
Fraser Valley Cancer Centre (FVCC)	(604)-930-2098	Toll-Free 1-(800)-523-2885
Vancouver Cancer Centre (VCC)	(604)-877-6000	Toll-Free 1-(800)-663-3333
Vancouver Island Cancer Centre (VICC)	(250) 519-5500	Toll-Free 1-(800)-670-3322

BC CANCER AGENCY SYSTEMIC THERAPY UPDATE FAX REQUEST FORM

FAX (604) 877-0585

bulletin@bccancer.bc.ca

TO SUBSCRIBE: FAX OR EMAIL YOUR REQUEST OR CALL @ 877-6098 LOCAL 2247

FOR URGENT REQUESTS PLEASE CALL (604) 877-6098 LOCAL 2247

OR TOLL-FREE IN BC 1-800-663-3333 LOCAL 2247

PLEASE FEEL FREE TO MAKE COPIES FOR YOUR COLLEAGUES

I WOULD PREFER TO RECEIVE THIS INFORMATION VIA:

E-mail (Word 6.0)

@

Fax

()

Attn:

UPDATES Please Fax-Back information below:

<input type="checkbox"/> All items	
Pre-Printed Orders:	
<input type="checkbox"/> GIA	<input type="checkbox"/> GIIRFUFA
<input type="checkbox"/> GIEFUP	<input type="checkbox"/> GOOVTOP
<input type="checkbox"/> GIENDO2	<input type="checkbox"/> GUSCARB
<input type="checkbox"/> GIIR	<input type="checkbox"/> LYCYCLO
<input type="checkbox"/> Index: Pre-Printed Orders	
Protocol Summaries: (also available on our website www.bccancer.bc.ca)	
<input type="checkbox"/> UBRAVTR	<input type="checkbox"/> GIIRFUFA
<input type="checkbox"/> BRAVTRNAV	<input type="checkbox"/> GUSCARB
<input type="checkbox"/> CNIME	<input type="checkbox"/> LUDOC
<input type="checkbox"/> ENAVD	<input type="checkbox"/>
<input type="checkbox"/> Index: Protocol Summaries (current month)	
Reimbursement (also available on our website www.bccancer.bc.ca)	
<input type="checkbox"/> Benefit Drug List (01 December 2001)	
<input type="checkbox"/> Class 2 Form (01 December 2001)	
<input type="checkbox"/> Filgrastim Usage Form (01 June 2001)	
<input type="checkbox"/> Undesignated Indication Form (November 2001)	
Systemic Therapy Update Index (also available on our website www.bccancer.bc.ca)	
<input type="checkbox"/> Jan-Dec 2000	
<input type="checkbox"/> Jan-Jun 2001	

REGIONAL CANCER CENTRE ACCESS

BULLETIN UPDATES	LOCATION
Pre-Printed Orders	H:\everyone\systemic\chemo\Orders\VCC
Index of Pre-Printed Orders	Index.doc
	GIA GIIRFUFA
	GIEFUP GOOVTOP
	GIENDO2 GUSCARB
	GIIR LYCYCLO
Protocol Summaries	H:\everyone\systemic\chemo\Protocol\tumour site"
Index of Protocol Summaries	Index_NT or Index_W6
	UBRAVTR GIIRFUFA
	BRAVTRNAV GUSCARB
	CNIME LUDOC
	ENAVD
Reimbursement	H:\everyone\systemic\chemo\Reimburs
Benefit Drug List (1 December 2001)	BenefitList.doc
Class 2 Form (1 December 2001)	Class2.doc
Filgrastim Usage Form (1 June 2001)	GCSF_form.doc
Undesignated Indication Form (November 2001)	Undesig.doc

For easy access, double-click your systemic chemo icon.

We appreciate your comments. Write us at bulletin@bccancer.bc.ca